Skip to Content
Merck
  • Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

Biochemical pharmacology (2010-10-26)
Katherine Ann Scott, John Barnes, Roger Clive Whitehead, Ian James Stratford, Karen Ann Nolan
ABSTRACT

The enzyme NAD(P)H quinone oxidoreductase (NQO1) can function both as a detoxifying enzyme as well as chaperone protein. The latter property has been extensively characterized by the use of dicoumarol which inhibits the chaperone properties of NQO1 in cells. However, the use of this compound is compromised by its multiple "off-target" effects. Coumarin-based compounds that are more potent than dicoumarol as inhibitors of NQO1 in cells have been identified (Nolan et al., Biochem Pharmacol 2010;80:977-81). The purpose of the work reported here is to evaluate the off-target effects of these compounds when compared to dicoumarol. A range of these substituted coumarins are identified that are significantly less toxic than dicoumarol in a panel of nine cell lines. Further a number of the compounds generate much less intracellular superoxide, and many of them also show a reduced ability to induce apoptosis when compared to dicoumarol. None of these effects correlate with the ability of the compounds to inhibit the enzymatic activity of NQO1 in cells. In conclusion, potent inhibitors of NQO1 have been identified that will be more pharmacologically useful than dicoumarol for probing the function of NQO1 in cells and tissues.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3,3′-Methylene-bis(4-hydroxycoumarin)